BACKGROUND: Abciximab reduced the combined endpoint of @entity204 , @entity583 ( @entity583 ) and target vessel revascularization in @entity1 with non-ST-segment elevation @entity1187 (NSTE-ACS) undergoing @entity301 ( @entity301 ) with stent implantation after a 600-mg loading dose of @entity1397 . The aim of the present study was to investigate the impact of abciximab on the evolution of @entity1002 ( @entity1002 ) in these @entity1 . METHODS: The current study included 1,158 @entity1 enrolled in the randomized, double-blind ISAR-REACT 2 (the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment) trial who had paired angiograms obtained at baseline and 6-8  months after randomization. Of them, 586 @entity1 received abciximab and 572 @entity1 received placebo. The primary outcome analysis was @entity1002 at 6-8-month follow-up. RESULTS: Baseline @entity1002 was comparable in @entity1 assigned to abciximab or placebo (53.2      12.6 vs. 53.7      12.1%; P  =  0.393). At 6-8-month follow-up angiography, there was no difference in @entity1002 between the abciximab and placebo groups (55.4      11.5 vs. 55.8      11.2%; P  =  0.743). Subgroup analysis of @entity1 with elevated baseline troponin (>0.03   g/L) also revealed comparable @entity1002 at follow-up in both treatment groups (P  =  0.527). The multivariate analysis identified age, arterial @entity101 , prior @entity583 , prior coronary artery bypass graft surgery, baseline @entity1002 , @entity583 at 30  days and repeat @entity301 as independent correlates of follow-up @entity1002 . CONCLUSION: Although abciximab reduced the 30-day and 1-year incidence of major adverse @entity299 in @entity1 with NSTE-ACS undergoing primary @entity301 after pre-treatment with a 600-mg loading dose of @entity1397 , the agent did not improve or impact on the evolution of @entity1002 over 6-8  months of follow-up.

Influence of abciximab on evolution of left ventricular function in XXXX with non-ST-segment elevation @entity1187 undergoing @entity301 after @entity1397 pretreatment: lessons from the ISAR-REACT 2 trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['acute coronary syndromes'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity301 :: ('MESH:D003327', 'Disease') :: ['PCI', 'percutaneous coronary intervention'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['clopidogrel'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1002 :: ('MESH:D018487', 'Disease') :: ['left ventricular ejection fraction', 'LVEF']
@entity1 :: (9606,Species) :: ['patients']
